# DESTINY-PanTumor01 (NCT05379985)

> Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05379985
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Revolution Medicines, Inc.
- Conditions: Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Advanced Solid Tumors
- Interventions: RMC-6236
- Enrollment: 754
- Primary outcome: Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs, including incidence and severity of findings in laboratory values and vital signs
- Primary outcome: Number of Participants with Dose-Limiting Toxicity (DLT)

## Indexed commentary on DESTINY-PanTumor01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 29
- YouTube: 9
- Podcasts: 6
- Bluesky threads: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=destiny-pantumor01-nct05379985

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05379985", "email": "<work email>"}; the inbox owner confirms by the emailed link.